Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Oct 14

PMID 36233469

Authors

Abi Selvarajah

Anne H Tavenier

Enrico Fabris

Maarten A H van Leeuwen

Renicus S Hermanides

Affiliations

Soon will be listed here.

Abstract

The pharmacological treatment strategies for acute coronary syndrome (ACS) in recent years are constantly evolving to develop more potent antithrombotic agents, as reflected by the introduction of more novel P2Y receptor inhibitors and anticoagulants to reduce the ischemic risk among ACS patients. Despite the substantial improvements in the current antithrombotic regimen, a noticeable number of ACS patients continue to experience ischemic events. Providing effective ischemic risk reduction while balancing bleeding risk remains a clinical challenge. This updated review discusses the currently approved and widely used antithrombotic agents and explores newer antithrombotic treatment strategies under development for the initial phase of ACS.

References

Wiviott S, Trenk D, Frelinger A, ODonoghue M, Neumann F, Michelson A . Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in.... Circulation. 2007; 116(25):2923-32. DOI: 10.1161/CIRCULATIONAHA.107.740324. View

Li J, Vootukuri S, Shang Y, Negri A, Jiang J, Nedelman M . RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2014; 34(10):2321-9. PMC: 4180209. DOI: 10.1161/ATVBAHA.114.303724. View

Ohlmann P, Reydel P, Jacquemin L, Adnet F, Wolf O, Bartier J . Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study. Circ Cardiovasc Interv. 2012; 5(1):69-76, S1. DOI: 10.1161/CIRCINTERVENTIONS.111.961425. View

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

Grosser T, Fries S, Lawson J, Kapoor S, Grant G, FitzGerald G . Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2012; 127(3):377-85. PMC: 3552520. DOI: 10.1161/CIRCULATIONAHA.112.117283. View

Angiolillo D, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass T . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49(14):1505-16. DOI: 10.1016/j.jacc.2006.11.044. View

Yusuf S, Mehta S, Chrolavicius S, Afzal R, Pogue J, Granger C . Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354(14):1464-76. DOI: 10.1056/NEJMoa055443. View

Stone G, Witzenbichler B, Weisz G, Rinaldi M, Neumann F, Metzger D . Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013; 382(9892):614-23. DOI: 10.1016/S0140-6736(13)61170-8. View

Safley D, Venkitachalam L, Kennedy K, Cohen D . Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2015; 8(12):1574-82. DOI: 10.1016/j.jcin.2015.04.031. View

10.

Sumaya W, Parker W, Fretwell R, Hall I, Barmby D, Richardson J . Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thromb Haemost. 2018; 118(7):1250-1256. PMC: 6202933. DOI: 10.1055/s-0038-1657768. View

11.

Wessler J, Giugliano R . Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials. Eur Heart J Cardiovasc Pharmacother. 2016; 1(2):97-106. DOI: 10.1093/ehjcvp/pvu008. View

12.

Vant Hof A, Berg J, Heestermans T, Dill T, Funck R, van Werkum W . Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008; 372(9638):537-46. DOI: 10.1016/S0140-6736(08)61235-0. View

13.

Rao S, Ohman E . Anticoagulant therapy for percutaneous coronary intervention. Circ Cardiovasc Interv. 2010; 3(1):80-8. DOI: 10.1161/CIRCINTERVENTIONS.109.884478. View

14.

Schupke S, Neumann F, Menichelli M, Mayer K, Bernlochner I, Wohrle J . Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381(16):1524-1534. DOI: 10.1056/NEJMoa1908973. View

15.

Sinnaeve P, Fahrni G, Schelfaut D, Spirito A, Mueller C, Frenoux J . Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2020; 75(20):2588-2597. DOI: 10.1016/j.jacc.2020.03.059. View

16.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

17.

Franchi F, Rollini F, Aggarwal N, Hu J, Kureti M, Durairaj A . Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. Circulation. 2016; 134(11):780-92. DOI: 10.1161/CIRCULATIONAHA.116.023402. View

18.

Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay J . Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369(11):999-1010. DOI: 10.1056/NEJMoa1308075. View

19.

Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D . Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013; 61(20):2060-6. DOI: 10.1016/j.jacc.2013.02.036. View

20.

Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica J, Sroka W . Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2015; 37(3):245-52. PMC: 4712351. DOI: 10.1093/eurheartj/ehv547. View